Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Product development and studies
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept amrx:ProductDevelopmentAndStudiesExpense.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
(1) For the three and six months ended June 30, 2026, the Affordable Medicines segment included recognition of deferred income and reimbursable R&D services of $0.8 million and $1.7 million, respectively, as reductions to product development and studies expense for services performed under the license agreement with Orion Corporation. For the three and six months ended June 30, 2025, the Affordable Medicines segment included recognition of deferred income and reimbursable R&D services of $0.9 million
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — product development and studies?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — product development and studies of -$800K in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s affordable medicines — product development and studies changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s affordable medicines — product development and studies decreased by 188.9% year-over-year, from $900K to -$800K.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — product development and studies?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — product development and studies has grown at a -39.0% compound annual growth rate (CAGR), from $23.2M to $5.25M.
- What does affordable medicines — product development and studies mean?
- Tracks expenditures related to clinical trials, product testing, and research activities necessary to bring new pharmaceutical products to market. It highlights the segment's commitment to innovation and future product pipeline growth.
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — product development and studies.
Connect your AI assistant and compare it to peers, right in your chat.
